×
About 68 results

Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Ca...
https://doi.org/10.1200/JCO.21.01532
Journal of Clinical Oncology : Official Journal of the Am... Tung NM, Zakalik D et. al.

Aug 4th, 2021 - ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely m...

New guidelines to treat bacterial infections.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577668
The Lancet. Infectious Diseases; Mushtaq A, Kazi F

Oct 26th, 2020 - New guidelines to treat bacterial infections.|2020|Mushtaq A,Kazi F,|drug therapy,epidemiology,virology,drug effects,enzymology,drug effects,drug therapy,microbiology,drug therapy,microbiology,drug effects,therapeutic use,metabolism,

International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diag...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7855268
Journal of Inherited Metabolic Disease; Altassan R, Radenkovic S et. al.

Jul 19th, 2020 - Phosphoglucomutase 1 (PGM1) deficiency is a rare genetic disorder that affects glycogen metabolism, glycolysis, and protein glycosylation. Previously known as GSD XIV, it was recently reclassified as a congenital disorder of glycosylation, PGM1-CDG. PGM1-CDG usually manifests as a multisystem disease. Most patients present as infants with cleft palate, liver function abnormalities and hypoglyce...

Suggestions for the care of patients with liver disease during the Coronavirus 2019 pan...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7174166
Clinics and Research in Hepatology and Gastroenterology; Ganne-Carrié N, Fontaine H et. al.

May 4th, 2020 - This document, written by the French Association for the Study of the Liver (AFEF) board, aims to provide information to physicians involved in the care of patients with liver disease during the Coronavirus disease (COVID-19) epidemic. These are not based on a systematic review of the literature and a rigorous evaluation using the GRADE method. These are recommendations based on feedback from C...

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Non...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080882
Clinical Pharmacology and Therapeutics; Theken KN, Lee CR et. al.

Mar 20th, 2020 - Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used analgesics due to their lack of addictive potential. However, NSAIDs have the potential to cause serious gastrointestinal, renal, and cardiovascular adverse events. CYP2C9 polymorphisms influence metabolism and clearance of several drugs in this class, thereby affecting drug exposure and potentially safety. We summar...

Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7344868
American Journal of Hematology; Bianchi P, Fermo E et. al.

Oct 26th, 2018 - Pyruvate kinase deficiency (PKD) is the most common enzyme defect of glycolysis and an important cause of hereditary, nonspherocytic hemolytic anemia. The disease has a worldwide geographical distribution but there are no verified data regarding its frequency. Difficulties in the diagnostic workflow and interpretation of PK enzyme assay likely play a role. By the creation of a global PKD Intern...

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of ...
https://doi.org/10.1200/JCO.2018.77.8738
Journal of Clinical Oncology : Official Journal of the Am... Wolff AC, Hammond MEH et. al.

May 31st, 2018 - Purpose To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 (HER2) testing in breast cancer guideline. Methods Based on the signals approach, an Expert Panel reviewed published literature and research survey results on the observed frequency of less common in situ hybridization (ISH) patterns to upd...

HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document f...
https://doi.org/10.1136/jclinpath-2017-204943
Journal of Clinical Pathology; Wong NACS, Amary F et. al.

Feb 14th, 2018 - The use of biologics targeted to the human epidermal growth factor receptor 2 (HER2) protein is the latest addition to the armamentarium used to fight advanced gastric or gastro-oesophageal junction adenocarcinoma. The decision to treat with the biologic trastuzumab is completely dependent on HER2 testing of tumour tissue. In 2017, the College of American Pathologists, American Society for Clin...

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatmen...
https://doi.org/10.1200/JCO.2017.76.7293
Journal of Clinical Oncology : Official Journal of the Am... Kalemkerian GP, Narula N et. al.

Feb 6th, 2018 - Purpose In response to advances in the field, the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recently updated their recommendations for molecular testing for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors. ASCO has a policy and set...

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline...
https://doi.org/10.1200/JCO.2016.69.4836
Journal of Clinical Oncology : Official Journal of the Am... Bartley AN, Washington MK et. al.

Jan 28th, 2017 - Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA. Objectives To establish an evidence-based guideline for HER2 testing in patients with GEA, formal...

Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5265697
Transplantation De Simone P, Fagiuoli S et. al.

Aug 9th, 2016 - Immunosuppression after liver transplantation (LT) is presently based on use of calcineurin inhibitors (CNI), although they are associated with an increased incidence of renal dysfunction, cardiovascular complications, and de novo and recurrent malignancies. Over the past decade, mammalian target of rapamycin inhibitors have received considerable attention as immunosuppressants because they are...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Ata...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785051
Clinical Pharmacology and Therapeutics; Gammal RS, Court MH et. al.

Sep 30th, 2015 - The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin. Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir. Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased f...

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibito...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717
Drugs Califano R, Tariq N et. al.

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The m...

Updated UK Recommendations for HER2 assessment in breast cancer.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4316916
Journal of Clinical Pathology; Rakha EA, Pinder SE et. al.

Dec 10th, 2014 - Human epidermal growth factor receptor 2 (HER2) overexpression is present in approximately 15% of early invasive breast cancers, and is an important predictive and prognostic marker. The substantial benefits achieved with anti-HER2 targeted therapies in patients with HER2-positive breast cancer have emphasised the need for accurate assessment of HER2 status. Current data indicate that HER2 test...

American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-b...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434978
Pancreas Conwell DL, Lee LS et. al.

Oct 22nd, 2014 - The diagnosis of chronic pancreatitis remains challenging in early stages of the disease. This report defines the diagnostic criteria useful in the assessment of patients with suspected and established chronic pancreatitis. All current diagnostic procedures are reviewed, and evidence-based statements are provided about their utility and limitations. Diagnostic criteria for chronic pancreatitis ...

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase t...
https://doi.org/10.1038/clpt.2014.97
Clinical Pharmacology and Therapeutics; Relling MV, McDonagh EM et. al.

May 3rd, 2014 - Glucose-6-phosphate dehydrogenase (G6PD) deficiency is associated with development of acute hemolytic anemia (AHA) induced by a number of drugs. We provide guidance as to which G6PD genotypes are associated with G6PD deficiency in males and females. Rasburicase is contraindicated in G6PD-deficient patients due to the risk of AHA and possibly methemoglobinemia. Unless preemptive genotyping has e...

Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV g...
https://doi.org/10.1111/liv.12363
Liver International : Official Journal of the Internation... Salmon-Ceron D, Arvieux C et. al.

Oct 22nd, 2013 - In HCV genotype 1-infected patients with HIV co-infection, tritherapy [HCV protease inhibitors (PIs) plus peg-interferon and ribavirin] has been shown to have an increased rate of sustained virological response. However, complex drug-to-drug interactions and tolerability issues remain a concern. Under the auspices of four French scientific societies of medicine, a committee was charged of estab...

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detectio...
https://doi.org/10.1111/bjh.12075
British Journal of Haematology; Bench AJ, White HE et. al.

Oct 13th, 2012 - Molecular genetic assays for the detection of the JAK2 V617F (c.1849G>T) and other pathogenetic mutations within JAK2 exon 12 and MPL exon 10 are part of the routine diagnostic workup for patients presenting with erythrocytosis, thrombocytosis or otherwise suspected to have a myeloproliferative neoplasm. A wide choice of techniques are available for the detection of these mutations, leading to ...

Urinary tract infection: clinical practice guideline for the diagnosis and management o...
https://doi.org/10.1542/peds.2011-1330
Pediatrics , Roberts KB

Aug 30th, 2011 - To revise the American Academy of Pediatrics practice parameter regarding the diagnosis and management of initial urinary tract infections (UTIs) in febrile infants and young children. Analysis of the medical literature published since the last version of the guideline was supplemented by analysis of data provided by authors of recent publications. The strength of evidence supporting each recom...

Guideline for phenotypic screening and confirmation of carbapenemases in Enterobacteria...
https://doi.org/10.1016/j.ijantimicag.2010.05.014
International Journal of Antimicrobial Agents; Cohen Stuart J, Leverstein-Van Hall MA et. al.

Jul 6th, 2010 - Adequate detection of carbapenemase-producing Enterobacteriaceae is crucial for infection control measures and appropriate choice of antimicrobial therapy. This guideline aims to improve the detection of carbapenemase-producing Enterobacteriaceae in the routine setting of clinical microbiology laboratories. Detection of carbapenemases in Enterobacteriaceae includes a screening step followed by ...